ALS (amyotrophic lateral sclerosis) is a fatal neurodegenerative disease that gradually affects a person's ability to move, speak and breathe. It advances differently in every patient. Now, ...

Life could feel uncertain when you’re diagnosed with ALS. You wonder how your life will change, and how quickly. Time suddenly feels precious. The truth is, everyone with ALS progresses differently.

Dr Arun Swaminathan tells Salong Debbarma how COYA 302’s FDA fast track status is shaping Coya’s next steps, from accelerating ALSTARS enrolment to aligning earlier with regulators on a path to ...

Nagoya University scientists develop a machine learning tool to uncover how ALS progresses in patients and offer clues to understand why some patients decline faster than others.

Long-term exposure to common air pollutants is associated with a higher risk of developing motor neuron disease (MND), as well as faster functional decline and poorer survival after diagnosis — even ...

- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...

Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease and is characterized by the progressive degeneration of upper and lower motor neurons. This devastating disorder ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

Darin Nakakihara doesn’t remember much from the day changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, and ...

COYA 302 represents a novel approach to ALS by targeting systemic immune dysfunction. The Food and Drug Administration (FDA) has granted Fast Track designation to COYA 302, an investigational biologic ...